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ABSTRACT
Objective: This study explored the annual occurrence/
incidence of bacterial infections, and their association
with chronic hyperglycemia and diabetic nephropathy,
in patients with type 1 diabetes.
Design: In a register-based follow-up study, we
investigated the frequency of bacterial infections in
patients with type 1 diabetes (n=4748) and age-
matched and sex-matched non-diabetic control (NDC)
subjects (n=12 954) using nationwide register data on
antibiotic drug prescription purchases and hospital
discharge diagnoses, collected between 1996 and
2009. Diabetic nephropathy was classified based on
the urinary albumin excretion rate (AER).
Results: The hospitalization rate due to bacterial
infections was higher in patients with diabetes
compared with NDCs (rate ratio (RR) 2.30 (95% CI
2.11 to 2.51)). The rate correlated with the severity of
diabetic nephropathy: RR for microalbuminuria was
1.23 (0.94 to 1.60), 1.97 (1.49 to 2.61) for
macroalbuminuria, 11.2 (8.1 to 15.5) for dialysis, and
6.72 (4.92 to 9.18) for kidney transplant as compared
to patients with diabetes and normal AER. The annual
number of antibiotic purchases was higher in patients
with diabetes (1.00 (1.00 to 1.01)) as compared with
NDCs (0.47 (0.46 to 0.47)), RR=1.71 (1.65 to 1.77).
Annual antibiotic purchases were 1.18-fold more
frequent in patients with microalbuminuria, 1.29-fold
with macroalbuminuria, 2.43-fold with dialysis, and
2.74-fold with kidney transplant as compared to
patients with normal AER. Each unit of increase in
glycated hemoglobin was associated with a 6–10%
increase in the number of annual antibiotic purchases.
Conclusions: The incidence of bacterial infections
was significantly higher in patients with type 1 diabetes
compared with age-matched and sex-matched NDC
subjects, and correlated with the severity of diabetic
nephropathy in inpatient and outpatient settings.
INTRODUCTION
Diabetes has previously been associated with
an increased risk of infections and mortality
due to infectious diseases.1–3 Patients with
diabetes have a twofold higher risk of
community-acquired enterobacterial, pneumo-
coccal, and streptococcal bacteremia as
compared with patients without diabetes.4–6
Type 1 diabetes in particular has been asso-
ciated with various defects in the innate and
the adaptive immune system, which in turn
may increase the risk of infections.7–9 Poor gly-
cemic control has been shown to be an import-
ant risk factor for infections.1 6 10 Even acute
hyperglycemia has been associated with ele-
vated levels of inﬂammation markers
in patients with diabetes.11 12 Notably, a
1 mmol/L increase in plasma glucose has
been associated with a 6–10% increased risk of
hospitalization for pneumonia, urinary tract
infections, and skin infections.13
Apart from hyperglycemia, other complica-
tions of diabetes may also predispose patients
to infections. Diabetic neuropathy can cause
impaired bladder emptying and thereby
increase the susceptibility to urinary tract
infections.14 Neuropathy in combination
with peripheral vascular disease can lead to
ulcerations in the skin and secondary infec-
tions.15 Long duration of diabetes increases
the risk of microvascular and macrovascular
complications and it has been estimated that
during their lifetime, approximately one-
third of patients with type 1 diabetes will
develop diabetic nephropathy, which is the
most common cause of chronic kidney
disease and end-stage renal disease (ESRD).
Owing to dialysis treatment and the lifelong
immunosuppressive drug therapy that follows
Key messages
▪ The prevalence of bacterial infections is greater
in patients with diabetes compared with non-
diabetic control subjects, and correlates with the
severity of diabetic nephropathy.
▪ Poor glycemic control is associated with an
increased number of antibiotic purchases in
patients with diabetes.
▪ Frequent use of antibiotics is associated with an
increased risk of the development of nephropa-
thy in patients with diabetes.
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kidney transplantation, ESRD has been associated with
an increased risk for bacterial infections.16 However,
studies have also shown that patients with chronic
kidney disease have an increased risk of infections and
infection-related mortality already before ESRD, caused
by reduced glomerular ﬁltration rate (GFR) and higher
urinary albumin excretion rate (AER).17 18 Chronic
inﬂammation, in turn, has been associated with the pro-
gression of diabetic nephropathy.19 20
Earlier studies have shown an increased risk of bacter-
ial infections in patients with diabetes; however, most of
these studies have focused on speciﬁc pathogens or spe-
ciﬁc infection sites such as skin, urinary tract, and
respiratory infections or severe infections necessitating
hospitalization.4–6 10 13 Consequently, the overall risk of
infectious diseases in patients with diabetes, both severe
infections and less severe infections treated outside of
hospitals, has not been established. Further, many of the
infection-related studies have not separated patients with
type 1 and type 2 diabetes. The principal aim of the
present study was therefore to assess the overall risk of
bacterial infections in patients with type 1 diabetes in
inpatient and outpatient settings. As a secondary aim, we
wanted to study the association with bacterial infections
and poor glycemic control, as well as their possible asso-
ciation with diabetic nephropathy.
METHODS
Design overview
Patients with type 1 diabetes were recruited, characterized,
and prospectively followed by the Finnish Diabetic
Nephropathy (FinnDiane) Study. The FinnDiane Study is
an ongoing nationwide multicenter survey, founded in
1997 to elucidate genetic and environmental risk factors
for diabetic nephropathy in patients with diabetes. The
study protocol is in accordance with the declaration of
Helsinki, and it has been approved by the local ethics com-
mittee at each study center. During the baseline visit,
details on clinical status, including age at diagnosis, insulin
therapy, and other medications, as well as presence and
severity of diabetic complications are registered by a stan-
dardized questionnaire, which is completed by the
patient’s attending physician based on medical ﬁles.
Fasting blood samples were collected during the baseline
visit from the patients for the measurement of glycated
hemoglobin (HbA1c), which was determined by standar-
dized assays at each study center. After the baseline visit,
the patients were followed and re-examined with prospect-
ive visits approximately in 3–5-year intervals. Subsequent
urine analyses were conducted for the follow-up of urinary
AER for the possible detection of the development and
progression of diabetic nephropathy. Nephropathy data
were also collected from the medical records.
Setting and participants
Follow-up started in 1996 and ended at death or at the
end of 2009. The FinnDiane patient cohort constituted
of 4748 patients with type 1 diabetes, of whom 52.7%
were males. For each patient with diabetes, three non-
diabetic control (NCD) subjects who were matched for
sex, age, and place of residence in the year of diagnosis
of diabetes were selected from the Finnish Public
Register Centre. After exclusion of individuals who died
or moved abroad before 1996, and those who were
entitled to special reimbursement of drug cost for dia-
betes mellitus between 1996 and 2009, the ﬁnal number
of control subjects was 12 954 (51.6% males). Type 1 dia-
betes was deﬁned as age at onset <40 years and perman-
ent insulin treatment started within 1 year after the
diagnosis of diabetes.
The severity of diabetic nephropathy was assessed by
the AER in at least two of three overnight or 24 h urine
collections: normal AER (<20 µg/min or <30 mg/24 h),
microalbuminuria (≥20 <200 µg/min or ≥30 <300 mg/
24 h), macroalbuminuria (≥200 µg/min or ≥300 µg/
24 h), and ESRD (deﬁned as dialysis treatment or
kidney transplantation). Urinary samples were not col-
lected, if the patients had fever or female patients were
menstruating. The time point for detection of nephro-
pathy progression was deﬁned as the year when the
AER, in subsequent urine samples collected during
scheduled prospective visits or measured in conjunction
with hospital visits, had in at least two of three samples
increased to the following stage of nephropathy, that is,
microalbuminuria or macroalbuminuria, or for ESRD
the date of the ﬁrst dialysis or kidney transplant. The
AER was not available at baseline for 579 patients. The
ﬁnal number of patients with conﬁrmed AER was there-
fore 4169. Altogether, there were 2664 patients with
normal AER, 544 with microalbuminuria, 625 with
macroalbuminuria, 85 with dialysis, and 251 with kidney
transplantation at the baseline visit. During the follow-up
time, 8.2% of the patients with normoalbuminuria,
18.2% with microalbuminuria, and 39.4% with macroal-
buminuria progressed to a higher level of albuminuria
or ESRD. Of the patients on dialysis, 27.1% underwent
kidney transplantation during the follow-up. Estimated
glomercular ﬁltration rates (eGFR), calculated with the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula, were used in the analyses as a com-
plementary method for diabetic kidney disease progres-
sion. When the analyses were conducted by eGFR, those
patients with unknown AER could also be included.
Instead, the patients with ESRD were excluded.
Data sources and outcomes
Information on hospitalizations due to bacterial infec-
tions and on antimicrobial drug prescription purchases
for each participant was drawn from two nationwide
registries: the Finnish Hospital Discharge Register, which
includes the diagnoses of all in-hospital treatment
periods, and the Finnish National Drug Prescription
Register, which includes all of the antibiotics purchased
from pharmacies outside hospitals. Infections treated in
hospitals were classiﬁed according to their most
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common etiology as bacterial, viral, fungal, or as
unspeciﬁed infections, using the primary and secondary
diagnoses from the Hospital Discharge Register, accord-
ing to the WHO International Classiﬁcation of Diseases
(ICD) 10th revision. The speciﬁc types and sites of the
hospital-treated infections are more closely speciﬁed in
online supplementary table S1. The risk of infections in
outpatients was assessed by acquiring information on the
annual outpatient prescription purchase frequencies of
antibiotics. Antibiotics were identiﬁed using the WHO
Anatomical Therapeutic Chemical (ATC) Classiﬁcation
System as drugs with an ATC code beginning with J01.
Since comorbidities may have an effect on the risk of
infections, common comorbidities were identiﬁed from
the Hospital Discharge Register, the Drug Prescription
Register, and the Drug Reimbursement Register for
patients with diabetes and NDCs. These comorbidities
included hypertension, cardiovascular disease (CVD
including ischemic heart disease and stroke), athero-
sclerosis, cancers, mental disorders, neurological dis-
eases, alcoholism, autoimmune diseases such as
rheumatoid arthritis, and respiratory disease (asthma
and obstructive pulmonary disease) as they belong to
the most common diseases in adults. The codes indicat-
ing certain diseases are available in online
supplementary table S2.
In a subanalysis, the number of antibiotic purchases
was compared between patients who had retained a
normal AER during the whole follow-up period
(n=2445) with their respective sex-matched and age-
matched NDCs (n=6560) to separate between the
impact of nephropathy and other possible effects of dia-
betes on antibiotic purchases.
In order to study more closely the association between
glycemic control and bacterial infections in patients with
diabetes, we examined the impact of the baseline
HbA1c on the total number of antibiotic purchases
made within a 3-year period: 1 year before the baseline
visit, during the examination year, and 1 year after the
baseline visit. The baseline HbA1c values were categor-
ized into ﬁve groups: <7%, 7–7.9%, 8–8.9%, 9–9.9%,
and ≥10%. Results are presented as incidence rate ratios
(RRs) with 95% CIs with the lowest value as reference.
The analyses were conducted separately in patients with
normal AER, and in patients with microalbuminuria or
macroalbuminuria. Patients with unknown nephropathy
status were excluded from these analyses.
Finally, the potential association between bacterial
infections and the development of diabetic nephropathy
was studied in a subset of patients with diabetes who
developed microalbuminuria during our follow-up
period (n=219). The annual number of antibiotic pur-
chases was counted from up to 4 years before, and
3 years after, the year of the diagnosis of incident micro-
albuminuria. For each of the patients, we assigned sex,
age, and diabetes duration (±2 years) matched controls
with diabetes who had retained a normal AER (n=874)
during the whole follow-up period. For these controls,
the number of antibiotic purchases was counted for the
same years as their corresponding patients with incident
microalbuminuria.
Statistical analysis
The cumulative number of hospitalizations due to infec-
tions and the number of antibiotic purchases were calcu-
lated for each individual annually from 1996 until death
or the end of the year 2009. In case of no hospitalization
or antibiotic purchase, the outcome was set to zero.
When the analyses were conducted according to nephro-
pathy groups, the follow-up started from the baseline
visit. The patients contributed the data during each year
to the corresponding nephropathy group. Since there
were only a few baseline visits in the years 1996 and 1997
in each nephropathy group, these results are shown
between 1998 and 2009.
The count data were highly skewed with excess zeros.
Thus, zero-inﬂated Poisson (ZIP) models were ﬁtted to
the data using the SAS NLMIXED procedure,21 which
takes into account the excess of zeros. Since one person
may have had multiple events, subject-speciﬁc random
effects were incorporated into the models. When the
outcomes between the patients with and without dia-
betes were compared, the predictors were calendar year
of the event and comorbidities. When the analyses were
conducted separately for these groups, the age in the
year 1996 and sex were included as covariates. In the
analyses according to nephropathy groups, the covariates
were age and duration of diabetes at baseline visit, sex,
calendar year, HbA1c, eGFR (not in the patients with
ESRD), smoking status, and comorbidities. The RRs of
hospitalization rates or antibiotic purchases and the 95%
CIs as well as predicted values were derived from the
ﬁnal ZIP models. Statistical analysis was performed using
the Statistical Analysis System (SAS) software (SAS 9.3,
Cary, North Carolina, USA).
RESULTS
The study cohort comprised of 12 954 NDCs and 4748
patients with type 1 diabetes (table 1). Between 1996
and 2009, the total number of follow-up years was
177 268 in the NDC group and 64 194 in patients with
type 1 diabetes. The total number of follow-up years in
each nephropathy group was as follows: normal AER
(19 804 years), microalbuminuria (4958 years), macroal-
buminuria (5821 years), dialysis (856 years), and kidney
transplant (2250 years). As expected, the median dur-
ation of diabetes increased along with increasing severity
of nephropathy. Hypertension, asthma, and mental dis-
orders were the most common comorbidities in patients
with diabetes and in NDCs. CVD and atherosclerosis
were much more frequent in patients with diabetes
(17.2% and 8.1%) compared with NDCs (3.9% and
0.3%) as they are well-known macrovascular complica-
tions of diabetes. Over 10% of patients with diabetes
died during follow-up as compared to 4.4% of NDCs.
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Table 1 Baseline characteristics, hospitalizations due to an infection, and antibiotic purchases according to nephropathy status
Normal AER
(type 1 diabetes)
Microalbuminuria
(type 1 diabetes)
Macroalbuminuria
(type 1 diabetes)
Dialysis (type 1
diabetes)
Kidney transplant
(type 1 diabetes)
All patients with
type 1 diabetes* NDC
n 2664 544 625 85 251 4748 12 954
Sex (male %) 48.8 58.5 60.6 61.9 59.0 52.7 51.6
Progressed (%) 219 (8.2) 99 (18.2) 246 (39.4) 23 (27.1)† NA NA NA
Deceased until 2009 (%) 2.9 9.4 24.4 72.6 44.1 10.5 4.4
Age at onset of diabetes (years) 17.2 [11.0–26.5] 12.7 [7.9–20.9] 11.4 [7.2–16.8] 12.5 [7.6–18.2] 11.2 [6.8–15.1] 14.9 [9.5–24.4] NA
Age (years) at baseline visit 37.1±12.8 39.3±12.5 41.9±10.5 47.1±9.3 44.9±8.2 38.9±12.4 NA
Age (years) in 1996 32.6±12.9 35.4±12.4 38.7±10.5 44.0±9.4 41.2±7.8 34.7±12.5 37.9±12.0
Duration of diabetes (years) 15.8 [8.4–25.5] 24.3 [16.4–32.7] 28.2 [22.9–33.8] 28.0 [24.4–34.6] 33.4 [27.3–37.6] 20.6 [11.3–30.4] NA
eGFR (mL/min/1.73 m2) 98 [84–111] 94 [76–109] 61 [39–85] NA NA 92 [73–108] NA
HbA1c (%) 8.2±1.4 8.9±1.6 9.1±1.5 9.2±1.7 8.5±1.5 8.5±1.5 NA
HbA1c (mmol/mol) 67±16 74±17 76±17 77±18 70±15 69±15 NA
History of smoking (%) 42.7 53.5 61.1 72.2 54.5 47.8 NA
Cancer n (%) 232 (8.7) 59 (10.9) 70 (11.2) 10 (11.9) 50 (19.9) 484 (10.2) 1095 (8.4)
CVD; stroke and IHD n (%) 226 (8.5) 96 (17.7) 222 (35.5) 58 (59.1) 144 (57.4) 819 (17.2) 501 (3.9)
Hypertension n (%) 964 (36.3) 392 (69.8) 595 (95.2) 85 (100.0) 251 (100.0) 2573 (54.2) 3220 (24.9)
Atherosclerosis n (%) 272 (1.5) 32 (5.9) 132 (21.1) 49 (58.3) 96 (38.3) 382 (8.1) 40 (0.3)
Mental disorders n (%) 641 (24.1) 138 (25.5) 205 (32.8) 34 (40.5) 79 (31.5) 1262 (26.6) 2893 (22.3)
Alcoholism n (%) 86 (3.2) 30 (5.6) 34 (5.4) 7 (8.3) 11 (4.4) 201 (4.2) 585 (4.5)
Neurological diseases n (%) 102 (3.8) 31 (5.7) 29 (4.6) 6 (7.1) 14 (5.6) 207 (4.4) 316 (2.4)
Rheumatoid arthritis n (%) 106 (4.0) 25 (4.6) 36 (5.8) 8 (9.5) 22 (8.8) 230 (4.8) 355 (2.7)
Asthma/COPD n (%) 652 (24.5) 166 (30.7) 187 (29.9) 21 (25.0) 48 (19.1) 1227 (25.8) 2923 (22.6)
Follow-up years‡ 19 804 4958 5821 856 2250 64 194 177 268
Antibiotic purchases (n)‡ 12 935 4643 6883 2762 6808 64 380 82 999
Annual purchase rate per person
(95% CI)‡
0.65 (0.64 to 0.66) 0.94 (0.91 to 0.96) 1.18 (1.15 to 1.21) 3.23 (3.11 to 3.35) 3.03 (2.95 to 3.10) 1.00 (1.00 to 1.01) 0.47 (0.46 to 0.47)
Hospitalizations (n)‡ 486 231 448 541 682 3980 2882
Annual hospitalization rate per
1000 person-years (95% CI)‡
24.5 (22.4 to 26.8) 46.6 (40.8 to 53.0) 78.3 (70.0 to 84.4) 632.0 (579.9 to 687.6) 303.1 (280.8 to 326.7) 62.0 (60.1 to 64.0) 16.3 (15.7 to 16.9)
*Patients without information about nephropathy status at baseline included.
†Kidney transplanted during follow-up.
‡Includes all patients who contributed data during each year in the corresponding nephropathy category. Demographic and clinical data are expressed as mean±SD, median [IQR], or total
number (%).
AER, albumin excretion rate; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; IHD,
ischemic heart disease; NA, not applicable; NDC, non-diabetic controls.
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Hospitalization due to infections
Data on infections leading to hospitalization were
obtained from the Finnish Hospital Discharge Register
(table 1). The patients with diabetes had a total of 3980
hospitalization events due to infections, of which 3229
(81.1%) were due to bacterial infection. The corre-
sponding number of events in the NDCs was 2882,
where 2102 (72.9%) infections had a bacterial etiology
(online supplementary table S1). The hospitalization
rate was higher in patients with diabetes compared with
NDCs, RR=2.30 (95% CI 2.11 to 2.51) in an adjusted
model. Patients with diabetes displayed an increasing
trend of hospitalizations between 1996 and 2009 with a
4% annual increase. In contrast, NDCs showed a slightly
decreasing trend with a 3% annual reduction in hospita-
lizations (table 2). Increasing age had a decreasing
effect on hospitalization risk in patients with diabetes
and NDCs. Men and women were equally hospitalized
in the diabetes group. In contrast, women in the NDC
group had a 44% lower hospitalization rate (RR=0.56,
95% CI 0.50 to 0.62, table 2) compared with men. In
both groups, all comorbidities increased the risk of hos-
pitalization except rheumatoid arthritis in the diabetes
group. Among comorbidities, atherosclerosis had the
largest effect in both groups and it increased the risk of
hospitalizations threefold: RR=3.16 (95% CI 3.11 to
5.45) for patients with diabetes; RR=3.09 (95% CI 1.87
to 3.29) for NDCs (table 2).
Time trends for annual hospitalization rates in differ-
ent nephropathy classes are shown in online
supplementary ﬁgure S1. The hospitalization rate
increased with the severity of diabetic nephropathy: the
mean hospitalization rate per 1000 person-years in
patients with normal AER was 24.5 (95% CI 22.4 to 26.8),
in patients with microalbuminuria 46.6 (95% CI 40.8 to
53.0), and in those with macroalbuminuria 78.3 (95% CI
70.0 to 84.4; table 1). In patients with ESRD, those on
dialysis had a higher hospitalization rate compared with
patients with a kidney transplant; 632 (95% CI 580 to
688) versus 303 (95% CI 281 to 327) per 1000 person-
years. The RRs when compared with the normoalbumi-
nuria group were 1.23 (95% CI 0.94 to 1.60), 1.97 (95%
CI 1.49 to 2.61), 11.2 (95% CI 8.1 to 15.5), and 6.72
(95% CI 4.92 to 9.18) for the microalbuminuria, macroal-
buminuria, dialysis, and kidney transplantation groups,
respectively. Hospitalizations were also inversely related
to eGFR (online supplementary ﬁgure S3). The risk was
the lowest and rather stable when eGFR was higher than
80 mL/min/1.73 m2, but started to increase rapidly
when eGFR showed reduced kidney function.
Online supplementary table S3 shows the hospitaliza-
tion RRs obtained from multivariate ZIP modeling
according to nephropathy status. Hyperglycemia was
strongly associated with hospitalizations in all other
groups except those on dialysis. Even in patients with
normal AER, each unit increase in HbA1c increased hos-
pitalizations by 26%.
Outpatient purchases of antibiotics
Data on antibiotic purchases were obtained from the
Finnish National Drug Prescription Register (table 1).
Patients with diabetes purchased more antibiotics annu-
ally compared with NDCs; 1.00 (95% CI 1.00 to 1.01) vs
0.47 (95% CI 0.46 to 0.47) (RR=1.71 (95% CI 1.65 to
1.77)). Antibiotic purchases increased during the study
period in patients with diabetes (2% annually) and in
NDCs (1% annually; table 2). Similarly, as for hospitali-
zations, increasing age had a decreasing effect on anti-
biotic purchases in patients with diabetes and NDCs. In
both groups, female patients purchased around 50%
more antibiotics; RR=1.54 (95% CI 1.46 to 1.63) for
patients with diabetes, 1.49 (95% CI 1.44 to 1.55) for
NDCs. Atherosclerosis had the most conspicuous
comorbidity effect in patients with diabetes (RR=2.94
Table 2 Multivariate ZIP-modeling and incidence RRs (95% CI) of the hospitalization due to infections and antibiotic
purchases in all patients with type 1 diabetes and NDCs
Hospitalizations Antibiotic purchases
All patients with
type 1 diabetes NDC
All patients with
type 1 diabetes NDC
Age (years) 0.98 (0.98 to 0.99) 0.97 (0.97 to 0.98) 0.99 (0.99 to 0.99) 0.99 (0.99 to 0.99)
Sex (men as reference) 0.95 (0.84 to 1.07) 0.56 (0.50 to 0.62) 1.54 (1.46 to 1.63) 1.49 (1.44 to 1.55)
Calendar year 1.04 (1.03 to 1.05) 0.97 (0.96 to 0.98) 1.02 (1.02 to 1.02) 1.01 (1.01 to 1.01)
Hypertension 2.45 (2.12 to 2.83) 1.59 (1.40 to 1.82) 1.56 (1.47 to 1.66) 1.31 (1.26 to 1.37)
CVD hard event 2.13 (1.81 to 2.49) 1.94 (1.53 to 2.47) 1.33 (1.23 to 1.44) 0.97 (0.88 to 1.06)
Atherosclerosis 3.16 (3.11 to 5.45) 3.09 (1.87 to 3.29) 2.94 (2.66 to 3.25) 1.76 (1.29 to 2.38)
Cancer 1.23 (1.02 to 1.48) 2.50 (2.10 to 2.96) 1.14 (1.04 to 1.24) 1.24 (1.17 to 1.33)
Mental disorder 1.42 (1.25 to 1.62) 1.28 (1.13 to 1.45) 1.24 (1.17 to 1.32) 1.31 (1.26 to 1.37)
Alcoholism 2.02 (1.57 to 2.59) 1.76 (1.41 to 2.18) 1.16 (1.02 to 1.32) 1.01 (0.93 to 1.10)
Neurological disease 1.67 (1.30 to 2.15) 2.16 (1.64 to 2.85) 1.13 (0.99 to 1.28) 1.10 (0.99 to 1.24)
Rheumatoid arthritis 1.24 (0.97 to 2.15) 1.61 (1.21 to 2.14) 1.15 (1.02 to 1.29) 1.36 (1.23 to 1.51)
Respiratory diseases (asthma/COPD) 1.18 (1.03 to 1.34) 1.62 (1.44 to 1.82) 1.47 (1.38 to 1.56) 1.97(1.89 to 2.05)
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; NDC, non-diabetic controls; RR, rate ratio; ZIP, zero-inflated
Poisson.
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(95% CI 2.66 to 3.25)), while respiratory diseases did
the same in the NDCs (RR=1.97 (95% CI 1.89 to 2.05);
table 2).
Patients with diabetes, who had retained a normal
AER during the whole follow-up period, had more anti-
biotic purchases than NDCs, RR=1.56 (95% CI 1.49 to
1.64). The risk ratio was only slightly decreased when
further controlled for comorbidities (RR=1.48 (95% CI
1.41 to 1.55)). Time trends for annual antibiotic pur-
chases in different nephropathy classes are shown in
online supplementary ﬁgure 2. The annual number of
purchases per person was 0.65 (95% CI 0.64 to 0.66) in
patients with normal AER, 0.94 (95% CI 0.91 to 0.96) in
patients with microalbuminuria, 1.18 (95% CI 1.15 to
1.21) in patients with macroalbuminuria, 3.23 (95% CI
3.11 to 3.35) in patients on dialysis, and 3.03 (95% CI
2.95 to 3.10) in patients with a kidney transplant (table 1).
The RRs obtained from the fully adjusted model were
1.18 (95% CI 1.07 to 1.30) for microalbuminuria, 1.29
(95% CI 1.15 to 1.44) for macroalbuminuria, 2.43 (95%
CI 2.08 to 2.84) for dialysis, and 2.74 (95% CI 2.35 to
3.17) for the kidney transplantation group compared to
patients with normal AER. Similarly, as for the hospitali-
zations, a reduced eGFR was associated with increased
antibiotic purchases (online supplementary ﬁgure 3).
There was a modest increase in purchases with decreas-
ing eGFR until 90 mL/min/1.73 m2, and this increase
was accelerated when eGFR decreased below 90 mL/
min/1.73 m2.
Online supplementary table S3 shows the antibiotic
purchase RRs obtained from multivariate ZIP modeling
according to nephropathy status. High HbA1c increased
purchases with a range of 6–10% per unit increase in
HbA1c across the nephropathy groups except in the
patients with ESRD. The impact of glycemic control on
antibiotic purchases was studied separately in (1) patients
with normal AER and (2) patients with microalbuminuria
or macroalbuminuria. Among patients with microalbumi-
nuria and macroalbuminuria, patients with poor gly-
cemic control (HbA1c ≥9%) had 1.25 (95% CI 1.08 to
1.45) times more antibiotic purchases than those with
good glycemic control (HbA1c <7%). In contrast, the
number of antibiotic purchases in patients with normal
AER was higher already when HbA1c was ≥7% (RR=1.22
(95% CI 1.14 to 1.31)). In patients with normal AER, the
number of antibiotic purchases leveled off when HbA1c
was ≥8% and in patients with microalbuminuria or
macroalbuminuria when HbA1c was ≥9% (ﬁgure 1).
We also wanted to assess whether the frequent use
of antibiotics could be associated with the progression of
nephropathy. As seen in ﬁgure 2, the mean number of
antibiotic purchases was higher in the group that devel-
oped microalbuminuria compared with the reference
group with normal AER. In patients with incident micro-
albuminuria, the number of antibiotic purchases was
higher at the time of nephropathy diagnosis (year 0)
compared with 4 years before the progression (year −4;
p=0.04 for time effect). In contrast, no signiﬁcant differ-
ences were observed in the number of antibiotic pur-
chases in patients with normal AER during the follow-up
(p=0.52 for time effect).
DISCUSSION
We performed a survey on bacterial infections in one of
the largest cohorts of patients with type 1 diabetes in the
world. By combining data from two different nationwide
registries that are mandatorily used in Finland, we were
able to study the incidence of infections causing hospi-
talization as well as infections treated in the outpatient
setting. Owing to the large number of patients and
follow-up years, we were also able to study the association
between bacterial infections and diabetic nephropathy.
We observed that bacterial infections were more
Figure 1 Association between
antibiotic purchases and glycated
hemoglobin (HbA1c) values in
patients with and without diabetic
nephropathy. Patients with normal
albumin excretion rate and
microalbuminuria/
macroalbuminuria are shown as
open and closed squares,
respectively. p Values (†p<0.05;
*p<0.001).
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common in patients with type 1 diabetes compared with
age-matched and sex-matched NDC subjects, and that
the incidence of bacterial infections increased in parallel
with the severity of diabetic nephropathy. The use of
antibiotics also correlated with the long-term glycemic
control in patients with normoalbuminuria, microalbu-
minuria, and macroalbuminuria. Frequent bacterial
infections and recurrent use of antibiotics were also asso-
ciated with an increased risk of incident microalbumi-
nuria in patients with diabetes.
Previous studies have shown that patients with diabetes
are at higher risk of hospitalization due to bacterial infec-
tions.13 22 On the basis of our hospital discharge register
data, we observed that the risk of hospitalization due to
bacterial infections was 4.3-fold higher in patients with
type 1 diabetes, compared with NDCs. Our results also
indicate that type 1 diabetes was associated with an
increased risk of less severe infections, treated outside of
hospitals. The overall number of annual antibiotic pur-
chases was, on average, twofold higher in patients with dia-
betes than in control subjects. This difference might partly
be explained by the general awareness of risks of infections
related to diabetes itself, and it is possible that the thresh-
old for clinicians to prescribe antimicrobial medications is
lower, and the antibiotics may be prescribed in a prophy-
lactic manner for patients with diabetes.
Albuminuria and reduced GFR have previously been
associated with an increased risk of infection-related
mortality.17 18 We observed that diabetic nephropathy at
all stages was a risk factor for bacterial infections.
Microalbuminuria did not increase the rate of hospital-
ization due to bacterial infections, but macroalbumi-
nuria doubled the rate compared with patients with
normal AER. Similar ﬁndings were found in the corre-
sponding results for outpatient antibiotic purchases,
where microalbuminuria increased the number of
annual antibiotic purchases by 1.2 times and macroalbu-
minuria by 1.3 times. ESRD has previously been shown
to be a strong risk factor for infectious diseases,16 and in
our study dialysis increased the rate of hospital-treated
bacterial infections by 11 times and the number of
annual antibiotic purchases by 2.4 times compared to
patients with diabetes and normal AER. Since long dur-
ation of diabetes increases the risk of diabetic complica-
tions, an important question that arose was how the
duration of diabetes inﬂuenced the incidence of bacter-
ial infections in patients with diabetes. We found that
each year of the duration of diabetes increased the
number of antibiotic purchases by 2.6%. However, when
adjusting for the nephropathy status, the increase was
1.4%. Patients with incident microalbuminuria pur-
chased signiﬁcantly more antibiotics at the time of
microalbuminuria diagnosis, compared with 4 years
before the progression. These observations could
suggest that bacterial infections may be associated with
the development of diabetic nephropathy.
Hyperglycemia has been shown to cause immunosup-
pression, and to increase the susceptibility to bacterial
Figure 2 Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1
diabetes. Annual number of antibiotic purchases in patients with type 1 diabetes and incident microalbuminuria (progressors,
n=219; closed squares), and their age, sex, and diabetes duration (±2 years) matched controls with type 1 diabetes that have
retained a normal albumin excretion rate during the whole follow-up period (non-progressors, n=874; open squares). The first
year of incident microalbuminuria is shown as year 0. Controls were matched for sex, age, and diabetes duration (±2 years).
Values are expressed as means with 95% CIs, and were adjusted for sex, HbA1c, and diabetes duration. A dashed horizontal
line indicates the level of significance between years −4 and 0 in the incident microalbuminuria group. p Values (#p<0.05;
*p<0.01;**p<0.001) apply to the differences in annual antibiotic purchase rates between progressors and non-progressors.
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infections.7–9 23 Several studies have demonstrated that
poor glycemic control is a considerable risk factor for
infections in patients with diabetes.1 10 24 Although
hyperglycemia could be a promoting factor for bacterial
infections, infections themselves may also cause hyper-
glycemia.25 Hence, a vicious cycle may arise as frequent
infections can worsen the glycemic control in patients
with diabetes, and conversely, chronic hyperglycemia
may facilitate the development of infections.26 We
observed that poor glycemic control correlated with the
number of antibiotic purchases, and that the relation-
ship did not differ between the various nephropathy
groups. The number of antibiotic purchases increased
by 6–10% for each unit increase in HbA1c at all stages
of nephropathy. As chronic hyperglycemia remains the
primary cause of metabolic, biochemical, and vascular
abnormalities in diabetic nephropathy, it could be
argued that poor glycemic control may be the link
between the progression of diabetic nephropathy and
the higher incidence of bacterial infections.
Some limitations must be considered in our study.
Data from the National Drug Prescription Register do
not reveal the type or site of the infection for which the
antibiotic treatment was required, only the compound
itself, and the number of packages sold are recorded in
the register. Based on the reports from the Finnish
Medicines Agency,27 hospitals annually purchase about
15–20% of all antimicrobial drug purchases in Finland,
and these purchases are not recorded in the National
Drug Prescription Register. Of note, most of these infec-
tion events are recorded in The Hospital Discharge
Register, and included in our study as infections that led
to hospitalizations. The Hospital Discharge Register also
has its own drawbacks. Owing to limitations of the
ICD-coding system, it can sometimes be challenging to
retrospectively establish the speciﬁc etiology of the infec-
tions—whether they are viral or bacterial in origin. It
should be noted that certain types of infections are
much more often encountered in patients with diabetes
than in patients without diabetes; for example, patients
with diabetic neuropathy are prone to foot ulcers, which
when infected can lead to osteomyelitis and possibly
even bacteremia. Also, physicians often have a lower
threshold for admitting patients with diabetes into hos-
pital care due to an infection, compared to patients with
an infection without any underlying disorders. This con-
tributes to the large difference in the number of hospi-
talizations seen in patients with diabetes when compared
with the NDC subjects.
Our study shows that bacterial infections are more fre-
quent in patients with type 1 diabetes compared with
age-matched and sex-matched NDCs, both in hospital
and outpatient settings. Although our study cannot
ascertain whether bacterial infections lead to the devel-
opment and progression of diabetic nephropathy, or if
the nephropathy predisposes the patient to bacterial
infections, it does show that there is a strong association
between the two. Bacterial infections could cause kidney
injury via endotoxins,28 29 or by direct invasion of patho-
gens, which may lead to inﬂammation and renal scar-
ring. Chronic hyperglycemia could also predispose to
infections as well as the progression of nephropathy.
More studies are required to elucidate which risk factors
increase the susceptibility to bacterial infections in
patients with type 1 diabetes, and to further investigate
the association between bacterial infections and the risk
of the development and progression of diabetic
nephropathy.
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